ImmunityBio (IBRX) EPS (Weighted Average and Diluted) (2019 - 2026)
ImmunityBio (IBRX) reported EPS (Weighted Average and Diluted) of -$0.62 for Q1 2026, down 313.33% year-over-year from $0.29 in Q1 2025, and down 933.33% quarter-over-quarter from -$0.06 in Q4 2025.
ImmunityBio (IBRX) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 8 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.62 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.62, down 313.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.85 (down 46.55% YoY), and the FY2025 annual result was -$0.38, up 38.71% from the prior year.
- EPS (Weighted Average and Diluted) eased to -$0.62 in Q1 2026 per IBRX's latest filing, from -$0.06 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.06 in Q4 2025 and troughed at -$0.62 in Q1 2026.
- A 5-year average of -$0.23 and a median of -$0.2 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2026: EPS (Weighted Average and Diluted) soared 76.32% in 2024, then plunged 313.33% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.27 in 2022, then slumped by 40.74% to -$0.38 in 2023, then soared by 76.32% to -$0.09 in 2024, then jumped by 33.33% to -$0.06 in 2025, then plunged by 933.33% to -$0.62 in 2026.
- Business Quant data shows IBRX's EPS (Weighted Average and Diluted) at -$0.62 in Q1 2026, -$0.06 in Q4 2025, and -$0.07 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn | -0.62 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.62 |
| Dec 31, 2025 | -0.06 |
| Sep 30, 2025 | -0.07 |
| Jun 30, 2025 | -0.10 |
| Mar 31, 2025 | -0.15 |
| Dec 31, 2024 | -0.09 |
| Sep 30, 2024 | -0.14 |
| Jun 30, 2024 | -0.20 |
| Mar 31, 2024 | -0.20 |
| Dec 31, 2023 | -0.38 |
| Sep 30, 2023 | -0.19 |
| Jun 30, 2023 | -0.32 |
| Mar 31, 2023 | -0.27 |
| Dec 31, 2022 | -0.27 |
| Sep 30, 2022 | -0.28 |
| Jun 30, 2022 | -0.24 |
| Mar 31, 2022 | -0.26 |
| Dec 31, 2021 | -0.23 |
| Sep 30, 2021 | -0.22 |
| Jun 30, 2021 | -0.23 |